BioLineRx is a clinical stage biopharmaceutical development company focused on identifying, licensing and developing promising therapeutic drugs. The company’s current pipeline consists of drugs that help patients with central nervous system diseases, cancer, cardiovascular and autoimmune diseases.
The company announced today that it has entered into a collaboration agreement for the purpose of developing and commercializing mutually selected, Compugen-discovered drug candidates for the treatment of various diseases. According to the agreement, Compugen will provide drug candidates, primarily peptides, which were identified as promising using its predictive drug discovery platforms.
BioLineRx will develop these drug candidates through Phase II clinical trials, with the goal of ultimately licensing them to pharmaceutical companies for advanced clinical development and commercialization.
The joint venture has been initialized with the selection of three Compugen-discovered peptides. Two of the peptides named CGEN-855 and CGEN-856 have already undergone animal studies and will enter BioLine’s main product pipeline as VL-7070. These peptides focus on preventing and treating cardiovascular disease by controlling inflammation and reducing hypertension.
The third peptide, CGEN-25017, has also undergone animal studies and will enter BioLine’s pipeline as BL-8010, and is intended for the treatment of diseases characterized by excessive growth of new blood vessels, such as cancer.
For additional information about BioLineRx and its exciting drug pipeline, please visit the company’s website at www.biolinerx.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html